Eli Wallace, Ph.D.

Eli Wallace, Ph.D., is BridgeBio Pharma’s Chief Scientific Officer in Residence for Oncology. Prior to joining BridgeBio, Eli was Chief Scientific Officer at Peloton Therapeutics, where he and his team discovered and developed first-in-class HIF2a inhibitor belzutifan for VHL Disease and metastatic renal cell carcinoma. Eli also worked as Director of Medicinal Chemistry at Array BioPharma, leading multiple research projects which produced eight new chemical entities that have entered human clinical trials for the treatment of cancer, including Mektovi®, which was approved to treat melanoma in 2018, Tukya®, which was approved to treat breast cancer in 2020, Koselugo®, which was approved to treat NF1 in 2020. Previously, Dr. Wallace worked as a medicinal chemist at Ciba-Geigy (now Novartis) and Glaxo Wellcome (now GlaxoSmithKline). He earned a B.A. in Chemistry from Lawrence University and a Ph.D. in Organic Chemistry from Colorado State University. Dr. Wallace was an NIH postdoctoral fellow at the University of South Carolina. He has co-authored more than 25 original research articles and invited reviews and is co-inventor on greater than 80-issued US patents.